Diagnosis and Treatment of Inflammatory Disease by Glycan Profiling of High Density Lipoprotein (HDL)
Individualized profile of HDL glycosylation indicating inflammatory disease riskPersonalized recommendations for the prevention and treatment of inflammatory disease
Diagnosis, prevention, and treatment of inflammatory disease
High density lipoprotein (HDL) is known for its role in removing “bad cholesterol” and reducing the risk of heart disease. HDL has also been linked to inflammation and immune function. The functional capacity of HDL as it relates to its glycan composition however has never before been examined or characterized. This makes glycoprofiling of HDL proteins a potentially powerful tool for developing personalized biomarkers for the diagnosis and treatment of inflammatory diseases. Researchers at the University of California, Davis have developed a method to diagnose an individual’s risk of inflammatory disease by measuring glycosylation levels of specific HDL proteins. Measurements from a patients’ blood sample are used to develop an HDL glycosylation profile that reflects the patient’s HDL’s immunomodulatory functional capacity. The profile values are then compared to control values representing healthy, and diseased populations, to assess the patient’s risk of inflammatory disease. A course of treatment (including diet, lifestyle, and other interventions) can then be recommended to positively alter the HDL glycan composition, improve HDL immunomodulatory function, and improve the patient’s health. This methodology breaks new ground by demonstrating a compositional aspect of HDL that is related to its immunomodulatory function, and applying that knowledge through a personalized approach to treating inflammatory disease.
Related Materials Additional Technologies by these Inventors Tech ID/UC Case 27616/2017-562-0 Related Cases 2017-562-0
USA
